Sarepta Therapeutics SRPT
NASDAQ SRPT
$17.50 -0.07 (-0.40%)
At close: Oct 2, 2026 · 4:00 PM EDT

Sarepta Therapeutics (SRPT) Asset Writedowns and Impairment (2010 - 2026)

Updated

Sarepta Therapeutics' Asset Writedowns and Impairment was $11.6 million in Q2 2026.

Analysis

Sarepta Therapeutics (SRPT) Asset Writedowns and Impairment (2010 - 2026) Analysis & Trends

On a trailing twelve-month basis, Sarepta Therapeutics' Asset Writedowns and Impairment was $14.2 million through Jun 30, 2026, up 446.2% year-over-year; for FY2025, it came in at $165.3 million.

  • Asset Writedowns and Impairment shows a four-year compound annual growth rate of 146.2% (FY2021 to FY2025).
  • In earlier years, Asset Writedowns and Impairment was $30.32 million in FY2023, $2.6 million in FY2022 (-42.2%) and $4.5 million in FY2021.
  • The Q2 2026 figure marks the lowest quarterly Asset Writedowns and Impairment since Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Sarepta Therapeutics 1.85 Bn -1.38 Bn 251.87 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 11.60 Mn
Dec 31, 2022 2.60 Mn
Sep 30, 2021 4.50 Mn
Dec 31, 2010 7,000.00
API Access

Sarepta Therapeutics Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=SRPT&period=max&api_key=YOUR_API_KEY